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Abstract
Antibiotics are used extensively in the treatment of various infections. Consequently, they can be considered
among the most important agents involved in adverse reactions to drugs, including both allergic and non-allergic
drug hypersensitivity [J Allergy Clin Immunol 113:832–836, 2004]. Most studies published to date deal mainly with
reactions to the beta-lactam group, and information on hypersensitivity to each of the other antimicrobial agents is
scarce. The present document has been produced by the Special Committee on Drug Allergy of the World Allergy
Organization to present the most relevant information on the incidence, clinical manifestations, diagnosis, possible
mechanisms, and management of hypersensitivity reactions to non beta-lactam antimicrobials for use by
practitioners worldwide.
Introduction
Adverse drug reactions (ADR) affect up to 10% of the
population, and in hospitalized patients this figure in-
creases up to 20% [1]. ADRs are classified into Type A
(predictable), which comprises about 80% of all ADRs,
and Type B (unpredictable). The predictable reactions
include toxicity (overdose), side effects, secondary ef-
fects, and drug interactions, whereas the unpredictable
reactions are intolerance, idiosyncracy, allergy and non-
allergic hypersensitivity.
Unpredictable hypersensitivity reactions occur only in
susceptible individuals, and can be produced through
immunologic (allergic) or non-immunologic mechanisms
[2]. Allergic reactions constitute 6 to 10% of all ADRs
[3,4]. Severe skin reactions such as Stevens-Johnson
Syndrome (SJS), Toxic Epidermal Necrolysis, Drug-induced
Hypersensitivity Syndrome (DiHS) and Acute Generalized
Exanthematous Pustulosis (AGEP) are considered hyper-
sensitivity reactions which can be life threatening and
for which the pathophysiology is not completely
understood. Patients presenting any of these reactions
need prompt recognition to avoid lifelong sequels and
cannot be re-exposed to the medication. No skin testing
or desensitization protocols are available for these reac-
tions, but patch testing may be helpful.
In the acute phase of an anaphylactic reaction, the ele-
vated level of serum tryptase (1-4 hours after anaphylaxis)
supports the diagnosis of drug hypersensitivity, IgE- or
non IgE-mediated.
The two groups of drugs more often responsible for
drug hypersensitivity reactions are antibiotics, especially
beta-lactams, and non-steroidal anti-inflammatory drugs.
Most publications on allergy to antibiotics have focused
on hypersensitivity to penicillins and cephalosporins, while
studies on reactions to each specific non beta-lactam are
scarce or involve only case reports or a small series of pa-
tients. Since new antibiotics are continuously introduced
into clinical use, reactions to newer compounds are likely
to increase in the near future. The Special Committee on
Drug Allergy of the World Allergy Organization organized
a group of experts in this field to update the current
knowledge on hypersensitivity reactions to non beta-
lactam antimicrobials and produce a reference document
that can be used worldwide by allergists and other
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practitioners. Some older antibiotics, which are currently
in use less often, were included.
For each drug we will review the current data on the
use of various in-vitro [5] and in-vivo diagnostic tests in-
cluding skin prick tests (SPT) and intradermal tests (IDT)
[6], measurement of specific IgE levels (immediate reac-
tions), intradermal tests with delayed reading and patch
tests (non-immediate reactions) [7] and drug provocation
tests (DPT) (immediate and non-immediate reactions) [8].
The use of the basophil activation test (BAT) [9], lympho-
cyte transformation test (LTT) [10] and the ELISPOT test
[11] for certain drugs will also be discussed. The uti-
lization of some of these diagnostic methods has been de-
scribed in several position papers [12,13].
Other than avoidance of the putative drug, manage-
ment of hypersensitivity reactions to non beta-lactam
antimicrobials may also include tolerance induction or
desensitization [14] where no alternative antibiotics can
be used and the benefits of reintroducing the drug out-
weigh the risks. Protocols have been described for some
of these medications.
Aminoglycosides
Introductory remarks
Aminoglycoside antibiotics have been used as an import-
ant part of the antibacterial drug arsenal for more than
50 years. They are indicated for polymicrobial and Gram
negative bacillus infections. As the prevalence of amino-
glycoside resistance has remained low, and emergence of
bacterial resistance during therapy has been rare, they
are still useful in clinical practice.
All aminoglycosides have an essential six-membered
ring with amino group substituents — hence, the name
aminocyclitol. The descriptor aminoglycoside results from
the glycosidic bonds between the aminocyclitol and two or
more amino-containing or non–amino-containing sugars.
Aminoglycosides are classified in two groups: (A) strepti-
dine group: e.g., streptomycin; (B) desoxystreptamine
group: e.g., kanamycin, amikacin, gentamicin, tobramycin,
neomycin. The most frequent and important side effects
of the aminoglycosides are nephrotoxicity and ototoxicity.
However, hypersensitivity reactions may occur [15].
Epidemiology and risk factors
Neomycin and streptomycin induce allergic reactions in
> 2% of treatments, gentamicin and amikacin in 0.1 to
2%, and kanamycin in 0.1 to 0.5%. No risk factors for al-
lergy to aminoglycosides have been reported. The preva-
lence of allergic contact reactions to topical neomycin
has been estimated between 1 and 29/10000 [16].
Neomycin is the most common sensitizer among top-
ical medications [17]. Some geographical differences
have been observed, since contact allergy to neomycin is
much more prevalent in the United States (10-11.8%,
mean 11.4%) than in Europe (1.2-5.4%, mean 2.6%) [18].
Clinical manifestations
Contact dermatitis from topical aminoglycoside is the
most frequent clinical manifestation associated with these
antibiotics, since neomycin, gentamicin and tobramycin
are widely used as cream, ointment, and eye or ear drops.
The occurrence of positive patch test reactions to amino-
glycosides increases with age in patients with chronic
dermatosis [19]. Highest frequencies of sensitization to
gentamicin have been found among patients with chronic
otitis externa [20]. However, gentamicin has been regarded
as less allergenic than neomycin [21]. It has been found
that 30% of persons who have stasis ulcers, 15% of patients
who have chronic otitis externa, and 5% of those who have
various chronic eczematous conditions become sensitized
by treatment with neomycin [22]. Caution must be taken
in patients under systemic administration, when the drug
can act as an internal allergen and reactivate eczema at a
previously affected site [23].
Other cutaneous manifestations like urticaria, maculo-
papular rash, fixed drug eruption and toxic epidermal
necrolysis (TEN) have been reported [15,24].
As reported recently, a patient developed a drug reaction
with eosinophilia and systemic syndrome (DiHS, DRESS)
induced by amikacin used for the treatment of septic arth-
ritis of the knee, which was confirmed by patch tests and
immunobiologic tests. Cross-reactivity with other amino-
glycosides was not observed in this patient [25].
Anaphylaxis is very uncommon. Few anaphylactic reac-
tions to streptomycin have been reported in which the drug
was present in contaminated food, or added to cell culture
media and administered during in vitro fertilization, or dur-
ing immunotherapy with phytohemagglutinin-lymphokine-
activated killer cells, or absorbed through skin lesions of a
subject affected by hand allergic contact dermatitis. In
most of these reactions an IgE-mediated mechanism was
suspected on the basis of skin-test positivity [25].
Gentamicin-induced anaphylaxis is rarely reported. In one
case report a positive prick test to gentamicin was found
and positive patch tests not just to gentamycin but also to
other aminoglycosides suggested a combined type I/type
IV sensitization [26,27].
Also there have been reports of adverse reactions to
inhaled tobramycin, including persistent eosinophilia
with severe bronchospasm [28] and cutaneous rash [29].
Pathogenesis
There is no definitive evidence of IgE-mediated immediate
hypersensitivity to aminoglycosides. IgG anti-streptomycin
antibodies have been demonstrated in patients with
haemolytic anemia. Contact dermatitis is mediated by
cell-mediated delayed hypersensitivity, and can be
Sánchez-Borges et al. World Allergy Organization Journal 2013, 6:18 Page 2 of 23
http://www.waojournal.org/content/6/1/18
demonstrated by means of patch testing. It is known that
neomycin is one of the most potent and frequent contact
sensitizers producing contact allergy all over the world.
Neomycin-induced contact dermatitis occurs especially in
patients with leg ulcers, atopic eczema, or chronic con-
junctivitis or otitis, and in patients with long-term cutane-
ous use of the drug [30]. Other systemic manifestations
such as eosinophilia, bronchospasm and serum sickness
are rarely observed.
Diagnosis
There is no validated skin test for the diagnosis of
immediate hypersensitivity to aminoglycosides. Positive
tests have been observed with tobramycin, gentamicin,
framycetin and streptomycin [26,27,31,32]. However, a
cautious approach must be taken when evaluating ana-
phylactic reactions to streptomycin, since systemic reac-
tions have been observed after prick test. The starting
concentrations suggested for prick tests range from 0,1
to 1 ng/mL, gradually reaching the concentration of
20 mg/mL if needed. If prick tests are negative intrader-
mal testing can be performed and non-irritating concen-
trations for intradermal testing have been established for
gentamicin and tobramycin to be 4 mg/mL [33]. There is
no evidence of positive serum IgE to aminoglycosides [26].
Patch tests with reading at 72 and 96 hours are recom-
mended for the diagnosis of non-immediate reactions. The
concentration for neomycin, gentamicin and tobramycin is
20% in petrolatum, and 1% for streptomycin [34]. The per-
centage of positive patch tests with neomycin in patients
with contact dermatitis is 2.5 to 3.6%, and in patients with
leg ulcers it varies from 9 to 15%. However, some patient
series show higher prevalences of sensitization [35]. Patch
tests with neomycin sulfate are positive in 5% of children
with contact dermatitis younger than 3 years [36].
Tests by prick, intradermal, intramuscular, or subcuta-
neous routes have not been standardized. Interferon-γ
ELISPOT has been recently utilized for the diagnosis of
amikacin-induced DIHS [21].
Management
Aminoglycosides should be avoided in patients with a
diagnosis of hypersensitivity. Cross-reactions among
aminoglycosides are common in patients with contact
dermatitis, approaching to 50% or more between those
from the desoxystreptamine group. Cross-reactivity is
less common to streptomycin (1-5%) [32]. However,
there are reports of eczematous contact-type dermatitis
after systemic administration of streptomycin in indi-
viduals who had become sensitized to neomycin and
had never been exposed to streptomycin [22]. Cross-
reactivity between neomycin, sisomycin and amikacin is
20%, and between neomycin, netilmycin and strepto-
mycin 1 to 5% [21,29].
Streptomycin shows no cross-reactivity with other
aminoglycosides that share deoxystreptamine [37], or
with those that are disubstituted-4,5 (neomycin and par-
omomycin), which show high cross reactivity with each
other, nor disubstituted-4,6 ones (tobramycin, kanamy-
cin, amikacin, gentamicin) whose reactivity with neomy-
cin is variable but always low at around 50% [32]. Some
experts recommend avoidance of all aminoglycosides in
neomycin-sensitive patients.
Desensitization is possible by the intravenous route in
patients with urticaria or angioedema due to strepto-
mycin [38,39] and for tobramycin both intravenously
and via inhalational route [40].
Chloramphenicol
Introductory remarks
This antibiotic produced by Streptomyces venezuelae
contains a nitrobenzene ring linked to propanol, with an
amide group binding to a derivative of dichloroaceta-
mide acid. Chloramphenicol is bacteriostatic against
Gram positive anaerobic and Gram negative aerobic and
anaerobic bacteria. Presently it is uncommonly used due
to the risk of hematologic adverse effects.
Epidemiology and risk factors
Hematological effects of chloramphenicol are idiosyn-
cratic effects, non-immunologically mediated. Generally
speaking, allergy to chloramphenicol is uncommon.
However, contact dermatitis can occur in up to 12-13.9%
of patients with venous leg ulcers [41,42]. Other risk fac-
tors include allergy to penicillin or ampicillin [43], severe
infection, and previous exposure to phenicols.
Clinical manifestations
The following adverse reactions have been observed: Sys-
temic reactions (anaphylactic shock [44,45], fever), cutane-
ous symptoms (urticaria [46], angioedema, maculopapular
rash, acute generalized exanthematous pustulosis [47],
contact dermatitis [48,49], bullous eruption, erythema
multiforme, exanthemas, fixed drug eruption, SJS, TEN,
respiratory symptoms (bronchospasm), hematologic mani-
festations (aplastic anemia [in 1 out of 21600 treatments],
and reduction of erythrocyte counts).
Pathogenesis
The mechanisms of reactions to chloramphenicol are
unknown. It is likely that the dichloroacetamide ring is
the major antigenic determinant.
Diagnosis
Skin prick tests and patch tests (chloramphenicol 1% in
petrolatum) have been proposed. Specific IgE in the
serum is not clinically relevant.
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Management
Avoidance of chloramphenicol and cross-reacting syn-
thetic derivatives is recommended.
Clindamycin
Introductory remarks
Clindamycin is a chemical derivative of lincomycin with
activity against aerobic Gram positive and anaerobic
Gram negative bacteria. Adverse effects of clindamycin
include diarrhea, pseudomembranous colitis, metallic
taste in the mouth, transient elevations in liver transami-
nases, granulocytopenia and thrombocytopenia. Hyper-
sensitivity reactions have decreased in frequency and are
relatively uncommon.
Epidemiology and risk factors
Clinical studies from the 1970s reported an incidence of
delayed rashes of approximately 10% with the use of
clindamycin [50,51]. A much larger study of 3,896 clin-
damycin administrations from a single U.S. hospital re-
ported an incidence of < 1% of adverse drug reactions
with only 5 probable cutaneous reactions in 3,462 pa-
tients, none of which were severe [52]. Risk factors for
clindamycin allergic reactions are unknown.
Clinical manifestations
The most common presentation for clindamycin allergy
is a delayed maculopapular exanthem, usually 7-10 days
after initiation of the drug [53]. However, other im-
munologic drug reactions have been reported including
anaphylactic shock, urticaria, angioedema, fixed drug
eruptions, bullous eruptions, AGEP, Sweet’s Syndrome,
SJS, and DiHS/Drug Rash with Eosinophilia and Sys-
temic Symptoms (DRESS) [54-61].
Pathogenesis
The pathogenesis of the most common form of clinda-
mycin allergic reaction, delayed maculopapular exan-
thems (MPE), has not been well studied. Patch tests have
been shown to be positive suggesting that these reactions
may involve T-cell mediated hypersensitivity [53].
Diagnosis
Skin prick tests (SPT) and intradermal tests (IDT) with
clindamycin have not been found to be useful for diag-
nosis. In a study of 31 subjects with histories suggestive
of immunologically mediated reactions, all patients were
subjected to prick and intradermal testing followed by
oral challenge. None of the patients had a positive prick
or intradermal test [62]. However, ten of 31 patients
(31%) had a positive oral challenge.
Patch testing with clindamycin has yielded mixed re-
sults with positive tests ranging between 15-30%. A study
from Germany of patients with a history suggestive of
clindamycin skin reactions found that 5/33 patients (15%)
had positive clindamycin patch tests using pulverized 150
mg tablets in 1 mL saline [63]. False negative patch tests
were seen in 6/26 patients. Oral challenges using hourly
dosing of 75, 150, 300, and 450 mg of clindamycin were
performed and 6 of 26 subjects had positive challenges, all
showing exclusively cutaneous manifestations. Another
study from Portugal of 30 patients with delayed cutaneous
reactions associated with clindamycin, found positive
patch tests in 30% of patients using clindamycin 10% in
petrolatum [53]. Oral challenges with clindamycin were
not performed in this study. Given the potential for false
negative reactions on patch testing, oral challenge is re-
quired to confirm tolerance to clindamycin.
Management
Most clindamycin delayed maculopapular exanthems do
not require specific therapy and resolve spontaneously
with cessation of the drug. A single case report of suc-
cessful drug desensitization to clindamycin in a patient
with HIV infection has been published [64]. This patient
had a delayed generalized exanthem to clindamycin,
confirmed by subsequent challenge. An induction of
drug desensitization was performed starting with a dose
of 20 mg every 8 hours followed by dose escalation daily
with 40, 80, 150, 300, then 600 mg over 6 days.
Dapsone
Introductory remarks
Dapsone is a sulfone antimicrobial that is a principal
drug in a multi-drug regimen recommended to treat lep-
rosy. Other uses as an antimicrobial include treatment
of malaria and Pneumocystis jiroveci pneumonia. Dap-
sone also has anti-inflammatory effects and has been
used to treat dermatitis herpetiformis and a wide variety
of other inflammatory dermatological conditions includ-
ing urticaria. Dapsone may cause a variety of adverse ef-
fects that may be categorized as pharmacologic, allergic,
or idiosyncratic.
Epidemiology and risk factors
Pharmacological hematologic adverse effects of dapsone
are common and dose-dependent. Patients with glucose-
6-phosphate dehydrogenase or glutathione reductase defi-
ciency are more susceptible to these hematologic effects.
Asymptomatic, clinically insignificant methemoglobinemia
occurs in most patients on dapsone at a dose of 100 mg
daily [65]. A dose-related hemolysis occurs in 4% of pa-
tients with HIV infection and in patients with stem cell
transplantation a frequency of hemolysis as high as 87% is
observed [66,67]. Hemolysis at doses of 100 mg daily is
generally mild and even in the stem cell transplant cohort
did not require cessation of dapsone. Agranulocytosis is a
rare idiosyncratic reaction associated with dapsone and
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occurs in 1:10,000-20,000 patients not otherwise ill
taking it as an antimalarial agent [68]. Patients with
dermatitis herpetiformis have a much higher risk of
agranulocytosis with an estimated risk 25-33 fold higher
than normal individuals.
The most common hypersensitivity reaction to dapsone
is a generalized exanthem. The incidence of this rash var-
ies widely in different reports and by underlying disease
being treated. A large study of 521 HIV patients treated
with dapsone 100 mg/d reported that 18% had “hypersen-
sitivity” reactions although no further details were pre-
sented [69]. A retrospective study of 75 HIV patients
treated with dapsone found that 16% reported a rash but
after a critical evaluation of each case, only 2 cases (3%)
were judged as “likely related” to dapsone [66]. In contrast,
in a study of 233 leprosy patients treated with dapsone
doses of 50-100 mg daily for 3 years none of them were
required to stop the treatment because of undesirable side
effects and the drug was well tolerated [70].
The most serious hypersensitivity reaction to dapsone
is known as the dapsone hypersensitivity syndrome
which is likely a form of DiHS/DRESS. A recent system-
atic review calculated an incidence of dapsone hypersen-
sitivity syndrome of 1.4% with an overall case-fatality of
9.9% [71]. Risk factors for fatalities from dapsone hyper-
sensitivity syndrome include mucosal involvement, rash,
hepatitis, older age, leprosy as an indication for dapsone,
and living in non-affluent countries.
Clinical manifestations
Methemoglobinemia with levels under 20% is usually
asymptomatic. Dyspnea, nausea, tachycardia and cyanosis
occur at higher levels and mental status changes, seizures
and arrhythmias occur with methemoglobin levels > 50%.
Hemolysis from dapsone is typically asymptomatic but
with more severe anemia patients may present with
dyspnea on exertion and fatigue. Agranulocytosis typically
presents acutely as fever and evidence of bacterial infection.
Maculopapular exanthem is the most common hyper-
sensitivity reaction to dapsone and is similar to other
drug reactions. Dapsone hypersensitivity syndrome has a
mean latency of 4 weeks prior to symptoms. A system-
atic review of the dapsone hypersensitivity syndrome re-
ported the following frequency of signs and symptoms:
fever (96%), rash (92%), hepatitis (82%), lymphadenop-
athy (74%), nausea and vomiting (61%), eosinophilia
(45%) and mucosal involvement (45%) [71].
Other less common manifestations of dapsone adverse
reactions include photodermatitis, eosinophilic pneumo-
nia, pancreatitis, hepatitis and SJS/TEN [72-75].
Pathogenesis
The common hematologic adverse effects of dapsone
(methemoglobinemia and hemolysis) are due to its
hydroxylamine metabolite. Dapsone hydroxylamine reacts
with oxyhemoglobin (Fe2+) to form methemoglobin
(Fe3+) [65] Dapsone-induced hemolysis is thought to in-
volve the generation of free radicals by dapsone hydroxyl-
amine and subsequent depletion of red blood cell (RBC)
glutathione stores [67]. The mechanism of dapsone in-
duced agranulocytosis is unknown and has been specu-
lated to involve cell control mechanisms as opposed to
toxicity or an immunologic reaction [68].
The mechanism of the dapsone hypersensitivity
syndrome is unclear [76]. It is unknown whether dapsone
hydroxylamine metabolites are causative of dapsone hyp-
ersensitivity syndrome. Circulating autoantibodies have
been reported after dapsone hypersensitivity but the path-
ogenic relevance of these antibodies is unknown [77].
Diagnosis
Dapsone-induced methemoglobinemia can be diagnosed
by a methemoglobin level measurement. Levels <15-20%
are usually asymptomatic; however in patients with
anemia, significant cardiac or respiratory diseases, or
other hemoglobin abnormalities, symptoms may occur
with levels < 15% [78]. Dapsone-induced hemolysis can
be detected via peripheral blood smear by the presence
of numerous bite cells or eccentrocytes [77]. Significant
hemolysis may be detected by measuring hemoglobin,
lactate dehydrogenase, indirect bilirubin and haptoglobin
levels. Agranulocytosis can be detected by loss of periph-
eral granulocytes on a complete blood count with differ-
ential counts.
There are no well-established criteria for the diagnosis
of dapsone hypersensitivity syndrome. However, as this
reaction is most likely a form of DiHS/DRESS, using the
criteria for diagnosis of DIHS/DRESS is appropriate
[79,80]. Specific drug diagnostic tests such as patch test-
ing have not been well studied for dapsone syndrome.
In a retrospective study, cross-reactivity between dap-
sone and trimethoprim-sulfamethoxazole was observed
in 13 out of 60 HIV-infected patients (21.7%) [81].
Management
Symptomatic methemoglobinemia from dapsone is typ-
ically treated with methylene blue. Cimetidine has also
been reported to be effective at reducing methemog-
lobinemia in most case series [78]. Vitamin E has been
reported to be partially protective against dapsone-
induced hemolysis [82]. Management of agranulocytosis
from dapsone involves stopping the drug and treating
any underlying infections.
Drug desensitization procedures have been reported
for dapsone since 1963. The largest and oldest case
series described 52 leprosy patients with a history of a
generalized papular dermatitis precipitated by dapsone,
some of whom likely had dapsone hypersensitivity
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syndrome [83]. An induction of drug tolerance proced-
ure has been reported starting with 12.5 mg dapsone
twice a week with gradual dose escalation until a dose
of 100 mg was reached in 15 weeks. Forty-eight patients
were successfully made tolerant; however, 26 patients
had recurrence of dermatitis during the procedure (1-10
times) before a tolerant dose was maintained. Another
case series in 14 HIV patients with fever and rash from
dapsone underwent an induction of drug tolerance pro-
cedure over 42 days starting with daily doses of 0.01 mg
[84]. All but one patient achieved drug tolerance to
dapsone. Finally, a case of a patient with dermatitis
herpetiformis with dapsone hypersensitivity syndrome
underwent a gradual reintroduction of dapsone starting
at 50 mg (the last tolerated dose) and increased the dose
gradually to 100 mg twice daily over 18 weeks with tol-
erance of the therapeutic dose [85].
Ethambutol
Introductory remarks
Ethambutol is one of the first-line drugs for the treatment
of active mycobacterial tuberculosis (TB) infection, and is
most commonly used in combination with other drugs
such as isoniazid, rifampicin, and pyrazinamide [86].
Although ethambutol is generally well tolerated, ADRs
including allergic reactions to this drug can occur. Of
those adverse reactions, optic neuritis is the main and
most frequently recognized. Serious hypersensitivity re-
actions, serious cutaneous and hematological reactions
have also been reported.
Epidemiology and risk factors
First-line anti-tuberculosis drugs are associated with sig-
nificant ADRs [87]. According to a clinical-based study,
female sex, old age, Asian ancestry and human immuno-
deficiency virus (HIV) infection have been suggested to
be associated with an increased incidence of reactions to
first-line anti-tuberculosis medications [88]. Among 430
patients, the incidence of all major adverse effects was
0.07 per 100 person-months of exposure for ethambutol
(95% CI 0.04– 0.10), which means adverse reactions to
ethambutol were uncommon compared to the other
anti-TB drugs [88].
Ethambutol is relatively safe compared to the other
anti-TB drugs and a prevalence of less than 1% of optic
neuritis has been reported in patients who received a 15
mg/kg dose [89]. Dermatologic reactions are relatively
uncommon and skin rash occurred in 0.15% [86]. Ser-
ious allergic reactions to ethambutol are only reported
as case series, suggesting a low incidence.
Clinical manifestations
Common reactions reported from field trials of first line
anti-TB drugs include skin rash and pruritus, hepatitis,
nausea/vomiting, thrombocytopenia, influenza-like illness,
arthralgias and neuropsychiatric symptoms [89].
However, most of these ADRs are usually induced by
anti-tuberculosis drugs other than ethambutol. The most
common problematic adverse reaction induced by eth-
ambutol is optic neuritis, which appears to be dose re-
lated and may cause decreases in visual acuity, color
blindness, and irreversible blindness. The changes in vis-
ual acuity may be unilateral or bilateral.
Ethambutol-induced skin reactions consist of hair loss,
rash, pruritus, urticaria, angioedema, skin striae, and ex-
foliative dermatitis [90]. Serious cutaneous adverse reac-
tions such as erythema multiforme, SJS, and TEN have
also been reported [91,92]. Skin rash, blood eosinophilia
and pulmonary infiltrates can rarely be observed [93].
There are case reports of DiHS/DRESS induced by
ethambutol [94,95]. Other adverse effects of ethambutol
include gastrointestinal intolerance, hyperuricemia, per-
ipheral neuropathy, and hematologic changes.
Pathogenesis
No studies on the pathogenesis of ethambutol-induced
allergic reactions have yet been reported. Optic neuritis
develops as a result of demyelination and not from an
inflammatory process. Recently, the association of HLA
markers with anti-TB drug-induced DiHS syndrome has
been published, suggesting a possible immunological in-
volvement [96].
Diagnosis
There is no gold standard test for the diagnosis of
ethambutol-induced allergic reactions. Oral provocation
test is not recommended when serious reactions occur.
Skin tests are usually negative. Patch tests may give valu-
able information.
Clinical information is important when trying to decide
the culprit drug causing an allergic reaction. However,
culprit drug(s) for these adverse reactions are usually not
clear and the assessment of a cause-effect relationship is
not easy because they are seldom used alone. Allergic re-
actions to combination therapy of the anti-TB drugs may
be due to drug allergy to more than one culprit drug.
Management
Testing of visual acuity before administration of etham-
butol and regular monitoring during drug treatment
are necessary for the early detection of optic neuritis.
Monthly evaluation of visual acuity is recommended
when doses higher than 15 mg/kg are administrated. De-
creased visual acuity usually recovers over a period of
weeks to months after ethambutol discontinuation, al-
though occasionally visual impairment and even blind-
ness can be permanent.
Sánchez-Borges et al. World Allergy Organization Journal 2013, 6:18 Page 6 of 23
http://www.waojournal.org/content/6/1/18
When serious allergic reactions occur, all the anti-TB
drugs should be promptly discontinued. With improve-
ment after discontinuation of all anti-TB drugs, sequen-
tial re-challenge is usually done cautiously, starting with a
small dose. When ethambutol is confirmed as the culprit
drug, anti-TB drug combinations without ethambutol can
be administered for the treatment of tuberculosis. Rapid
desensitization has been utilized successfully in 5 patients
with various ethambutol reactions [97].
Isoniazid
Introductory remarks
Isoniazid is a component of first-line treatment for ac-
tive TB and is administered as well for treatment of la-
tent TB [98,99]. Well recognized adverse effects from
isoniazid include elevation of liver enzymes, drug fever,
peripheral neuropathy, pruritus, and very infrequently a
rash. SJS has been described [100]. There is a single
report of anaphylaxis [101]. Isoniazid inhibits both di-
amine oxidase and monoamine oxidase, thus allergic-
like reactions can occur when foods containing hista-
mine or tyramine are ingested [102].
Epidemiology and risk factors
In 10-20% of patients receiving first-line medications for
TB disease, it can be anticipated that there will be
asymptomatic, typically reversible elevations up to at
least 5 times the upper limit of normal for alanine ami-
notransferase (ALT) and aspartate aminotransferase
(AST). The incidence of clinical hepatitis ranges from
0.1% to 0.6% [99]. This incidence increases to approxi-
mately 1.6% if isoniazid and other medications excluding
rifampicin are administered. Clinical hepatitis is reported
to occur in 2.7% of patients receiving both isoniazid and
rifampicin. Risk factors include age (50-64 years), under-
lying liver disease, especially associated with alcohol, the
post-partum period, and being a Hispanic woman.
Deaths from clinical hepatitis occur in less than 1/5000
patients. Peripheral neuropathy is considered dose re-
lated with an incidence < 0.2% [100]. Risk factors include
nutritional deficiency (reason for supplementation with
vitamin B6, pyridoxine, 25 mg daily), alcoholism, dia-
betes mellitus, human immunodeficiency virus (HIV) in-
fection/acquired immunodeficiency syndrome (AIDS),
renal failure, pregnancy and lactation. As many as 20%
of patients develop anti-nuclear antibodies, but systemic
lupus erythematosus that involves discontinuation of iso-
niazid occurs in < 1% of patients [99].
The precise incidence of SJS/TEN from isoniazid has
not been established, although it seems to be rare. HIV
infection is well recognized as a risk factor for drug
hypersensitivity. In a series of 820 patients undergoing
observed therapy for TB Disease, 47 patients (5.7%) de-
veloped cutaneous adverse reactions, with pyrazinamide
being the most likely drug [103]. Isoniazid-associated cu-
taneous reactions were noted in 0.98% of patients [103].
Clinical manifestations
Allergic reactions to isoniazid include rashes that are
morbilliform or lichenoid (violaceous, flat topped, prur-
itic papules), flushing, and extremely rarely, SJS/DiHS/
DRESS [99,100]. In a study where incriminated anti-TB
medications were re-administered to patients having
experienced cutaneous adverse drug reactions, often be-
ginning at 1/8 of the total dose, reactions to isoniazid
were reproducible in 5/36 (13.8%) patients [100]. In this
series, the 5 reproduced reactions were SJS, DiHS and
lichenoid rash, typically within the first 72 hours. For
comparison, reproducible reactions occurred with rifam-
picin in 13/37 (35%) patients, and with pyrazinamide in
3/15 (20%) patients. These data emphasize that in pa-
tients receiving multiple medications for TB disease and
in whom medications for HIV/AIDS may be adminis-
tered concurrently, it is often difficult to ascertain the
exact putative drug. Frequently, patients receiving iso-
niazid experience a rash in the first month of therapy
(median onset at 20 days). In a series of gold miners
receiving treatment for latent TB, cutaneous rashes
occurred in 61 patients (0.25%), most of which were
considered mild or moderate in severity. Pruritus was re-
ported in the first month by 4.3% of gold miners being
treated for latent TB, and by 5.3% of patients when com-
bining symptoms from the visits at 3 and 6 months of
treatment [104]. For comparison, the authors noted that
pruritus had been reported by 8.3% of patients in the 2
week period prior to initiation of isoniazid. These data do
suggest that the benefits of continuing isoniazid in pa-
tients with pruritus outweighs the risks of treatment, but
careful monitoring for the presence of rash is needed.
Drug fever from isoniazid ranges from 38-40°C and by
definition resolves within 72 hours of discontinuation of
the incriminated medication [105]. Peripheral neur-
opathy is characteristically mild, but patients with more
than mild preexisting peripheral neuropathy should not
receive treatment with isoniazid [104].
Pathogenesis
Evidence for isoniazid hypersensitivity and toxicity reac-
tions includes studies from hepatitis, hepatic necrosis and
drug induced lupus erythematosus. One notion is based
on the metabolism of isoniazid to reactive or immu-
nogenic molecules. Initially, isoniazid is acetylated by N-
acetyltransferase 2 to acetylisoniazid and then hydrolyzed
to acetylhydrazine, which then is oxidized to highly react-
ive metabolites that acetylate various molecules [106]. The
acetylated molecules damage cells directly or form im-
munogenic protein complexes that result in tissue injury.
It had been proposed that the rapid acetylator of isoniazid
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phenotype would be protected from hepatic damage. In
studying both the genetics of N-acetyltransferase 2 and
the pharmacokinetics of acetylation by determining the
ratio of serum acetylisoniazid/isoniazid after ingestion
of 300-400 mg of isoniazid, the functional contribution
of genetic polymorphisms and acetylation phenotypes
could be elucidated more precisely [107]. In patients
who developed hepatitis, some polymorphisms of N-
acetyltransferase 2 were associated with slow acetylation
(higher serum concentrations of isoniazid and lower ra-
tios of acetylisoniazid/isoniazid). Other genetic mutations
in drug-metabolism were not associated with isoniazid
hepatitis. Continued research is required as not all rapid
acetylator patients are protected from hepatitis.
Diagnosis
Allergic drug reactions typically follow the “rule of 2 s”
in that most reactions occur in the first 2 minutes to 2
months after initiating therapy [108]. In the setting of
possible isoniazid associated cutaneous reactions, other
medications used for TB or HIV/AIDS may be the cause
as opposed to isoniazid. Since specific skin tests or
in vitro tests are often not available to confirm isoniazid
as the culprit, in some settings, such as treatment of TB
disease or for treatment of latent TB, graded challenges
may be indicated to confirm or, more preferably, exclude
drug hypersensitivity.
Non-allergic reactions such as elevations in hepatic
transaminases do not necessitate discontinuation of iso-
niazid unless clinical hepatitis or more than 5-fold in-
creases over the upper limits of normal occur. Clinical
judgment is required as other host factors can increase
the risk of isoniazid hepatotoxicity.
Management
As noted above, some patients with pruritus associated
with initiation of isoniazid can have their therapy contin-
ued in the absence of a new rash. Even patients with
morbilliform rashes may receive concomitant pharmaco-
therapy (histamine 1 receptor antagonists, topical anti-
pruritus treatments and topical corticosteroids) for
symptom relief so as to be able to continue the essential
isoniazid. Often, a more serious rash that is generalized,
erythematous, raised and potentially blistering, would re-
sult from another medication (or viral infection) rather
than from isoniazid. Consultation with an allergist-
immunologist to help prioritize the potential culprit
medications or other causes of the new rash is recom-
mended where feasible. Graded challenges or desensiti-
zations with isoniazid may be required, and various
protocols can be utilized. Starting doses in adults have
been at 40-50 mg, but sometimes lower doses may be
advisable. Daily increments, such as reaching 300 mg in
3-7 days have been reported [100,109].
The patient and referring physician or health care pro-
fessional need to accept the possibility that a serious cu-
taneous reaction that requires oral or intravenous
corticosteroids could occur during or after the graded
challenge. If the possibility of future systemic corticoste-
roids is refused, the graded challenge should not be
undertaken. Fortunately, most graded challenges with
isoniazid would be expected to be carried out safely and
with a favorable benefit-risk ratio.
Macrolides
Introductory remarks
Macrolides are classified according to the number of
carbon atoms in their lactone ring: 14-membered (erythro-
mycin, troleandromycin, roxithromycin, dirithromycin, and
clarithromycin), 15-membered (azithromycin), and 16-
membered (spiramycin, rokitamycin, josamycin, and
midecamycin). Macrolides exhibit a good activity against
Gram-positive aerobes and some Gram-negative aerobes.
Epidemiology and risk factors
Hypersensitivity reactions to macrolides are relatively
uncommon (0.4% to 3% of treatments) [110].
Clinical manifestations
Cases of immediate reactions in the form of urticaria/
angioedema, rhinoconjunctivitis, and anaphylaxis, and
nonimmediate reactions, such as maculopapular rash,
non-immediate urticaria, contact dermatitis, fixed drug
eruptions, and toxic epidermal necrolysis, have been re-
ported in children and adults [110-115].
Diagnosis
A study by Empedrad et al [33] on skin testing found non-
irritating concentrations for intradermal testing of erythro-
mycin (0.05 mg/mL) and azithromycin (0.01 mg/mL).
However, data from the literature indicate that in evaluat-
ing hypersensitivity reactions to macrolides, the sensitivity
of skin tests is low; therefore, provocation tests are often
necessary [110,112,114]. Specifically, Seitz et al evaluated
125 subjects with suspected macrolide allergy. IDT with
erythromycin, clarithromycin, and azithromycin were per-
formed at a concentration of 0.01 mg/mL. All skin tests
were negative in the 53 patients with immediate reactions,
whereas one of the 72 subjects with non-immediate reac-
tions developed a delayed SPT positivity to roxithromycin
at 50 mg/mL. Challenges were negative in the 47 subjects
with immediate reactions who underwent such tests,
whereas they were positive in 4 of 66 patients with non-
immediate reactions [115]. A study by Mori et al [114]
evaluated 64 children with histories of clarithromycin
hypersensitivity by performing intradermal tests at a
concentration of 0.5 mg/mL, and they subsequently
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underwent challenges. Intradermal test sensitivity and spe-
cificity were 75% and 90%, respectively.
In single cases, skin tests proved to be useful in diagnos-
ing IgE-mediated hypersensitivity to macrolides such as
erythromycin, spiramycin, azithromycin, and roxithromycin
[110,116-118].
There are also reports of positive responses to patch
tests at concentrations up to 10% in petrolatum or
dimethylsulfoxide in subjects with non-immediate reac-
tions (e.g., fixed drug eruptions and contact dermatitis)
to macrolides such as erythromycin and azithromycin
[110,111,113].
With regard to in vitro tests, there are reports of posi-
tive serum specific IgE assays in single cases [116], while
in the study by Seitz et al [115], Basophil activation Test
(BAT) and Lymphocyte Transformation Test (LTT) were
negative in 10 and 7 subjects, respectively.
Management
As far as the management of subjects with macrolide
hypersensitivity is concerned, cross-reactivity among
14-membered macrolides (erythromycin, clarithromycin,
and roxithromycin) has been detected in single patients
with either immediate [117] or non-immediate [111] re-
actions to erythromycin on the basis of positive re-
sponses to prick tests or patch tests. Milkovic-Kraus et
al described two subjects with allergic contact dermatitis
to azithromycin who showed cross-reactivity with azi-
thromycin intermediates, including erythromycin [113].
However, the paucity of reports of allergic contact
dermatitis to azithromycin makes it difficult to advise
avoidance of other macrolides. In any case, it would ap-
pear that macrolide hypersensitivity is unlikely to be
cross reactive. Desensitization has been successful in a
few cases of macrolide hypersensitivity [110,118].
Pyrazinamide
Introductory remarks
Pyrazinamide (PZA), a synthetic analog of nicotinamide,
is one of the most effective antituberculous drugs.
Epidemiology and risk factors
Hypersensitivity reactions to anti-TB drugs are reported
in 1-5% of patients. Among 430 patients, the incidence
of all major adverse effects was 1.48 per 100 person-
months of exposure (95% CI 1.31-1.61) for pyrazina-
mide, which was the highest risk among other first line
anti-TB medications [88]; cutaneous manifestations are
the most frequent, and PZA has been involved in most
such cases as it is often used in combination with isonia-
zid, rifampicin and ethambutol in the initial treatment of
TB [119]. Pyrazinamide-induced adverse events were as-
sociated with patients aged over 60 and born in Asia.
Clinical manifestations
It is difficult to identify the responsible compound in sub-
jects treated simultaneously with 4 different antitubercu-
lous drugs. In particular, PZA may cause hypersensitivity
reactions, such as flushing, immediate (i.e., occurring
within one hour after the last drug administration) itchy
rashes [120-125], and anaphylaxis [126,127]. PZA can also
provoke dose-dependent cytolytic hepatitis.
Pathogenesis
With regard to the pathogenic mechanisms of these
reactions, considering that nicotinamide – from which
PZA is synthesized regularly – can cause truncal and fa-
cial flushing and itching, presumably prostaglandin-
mediated, a similar mechanism has been hypothesized
for PZA-induced flushing and skin rash [126]. Moreover,
Soyez et al observed an increase of plasma histamine
levels on the first day of a desensitization protocol ap-
plied in a subject who had reacted to PZA [120]. In the
case report by Shorr and Trotta [121], however, biopsy
of the rash revealed a spongiotic dermatitis with eosino-
phils and necrotic keratinocytes, which indicates that
other pathogenic mechanisms might be involved.
Diagnosis
To our knowledge, there are no reports of cases of
hypersensitivity reactions to PZA which were assessed
with the currently available in vitro tests. As far as skin
testing is concerned, in a subject who had experienced
an anaphylactic reaction to PZA, an IgE-mediated mech-
anism was diagnosed by Bavbek et al [127] on the basis
of a positive SPT at a concentration of 500 mg/mL in
normal saline.
In some cases of immediate skin rashes after the first
dose of PZA, hypersensitivity was diagnosed by re-
administering PZA [120-126]. It is interesting to note
that Mulliez et al did not observe any increase of serum
tryptase or urinary histamine in a patient who reacted to
PZA re-administration [125].
A slower PZA re-administration has been successful in
a few cases of PZA hypersensitivity [122-125], including
the one with a positive prick test [127]. In conclusion,
PZA hypersensitivity should be suspected if an immedi-
ate skin rash develops at initiation of an antituberculous
therapy.
Management
In subjects with cutaneous hypersensitivity reactions dur-
ing antituberculous therapy, if the skin involvement is not
severe, sequential reintroduction of the suspected drugs
first at low, then at full dosage should be attempted. PZA
should be reintroduced last and at a dose lower than the
full therapeutic one, and then administered with a step-
wise dose increment.
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Quinolones
Introductory remarks
Quinolones are usually well-tolerated antibiotics that are
being increasingly prescribed because of their effective-
ness against Gram-positive and Gram-negative bacteria.
These are particularly used in aged populations with the
subsequent risks of severe reactions like anaphylaxis.
Epidemiology and risk factors
The frequency of hypersensitivity reactions to quinolones
seems to have increased over the last few years and most
of these reactions are of the immediate type [128]. The
frequency of anaphylaxis induced by quinolones has been
estimated to be 1.8-2.3 per 10,000,000 days of treatment
[129]. Moxifloxacin was the quinolone most frequently in-
volved, followed by levofloxacin and ciprofloxacin [130].
The rate of anaphylactic reactions to levofloxacin is re-
ported to be 1 per 1 million patients [131].
Atopy seems to be a risk factor for immediate hyper-
sensitivity [132]. The reactions induced by moxifloxacin
were more severe than those induced by ciprofloxacin.
In a large group of patients with quinolone hypersensi-
tivity in Spain, 75% of reactions induced by moxifloxacin
and 54% of those induced by ciprofloxacin were ana-
phylactic [133].
Clinical manifestations
Most hypersensitivity reactions to quinolones are of
the immediate type, mainly urticaria and anaphylaxis
[128-133]. Nonimmediate reactions are less frequent,
and include maculopapular exanthema, fixed drug
eruptions, photoallergy, AGEP, SJS, and TEN [128].
Pathogenesis
In immediate-type reactions, an IgE-mediated mechan-
ism is involved, at least in half of the patients. This was
shown by Manfredi et al [132] using radioimmunoassay
(RIA), and Aranda et al confirmed that result with RIA
and basophil activation test (BAT). When the RIA was
repeated after some months, there was a decrease in IgE
response, becoming negative in some patients [133].
A T cell–mediated pathomechanism is likely to be in-
volved in exanthematous reactions and phototoxicity
[134]. Cross-reactivity is common between first and
second-generation quinolones, less common with third
and fourth generation quinolones. It is often unpredict-
able [135,136]. Immediate hypersensitivity to quinolones
has been recently associated with neuromuscular block-
ing agent sensitization [137].
Diagnosis
The diagnosis can be difficult because skin testing can in-
duce false positive and false negative results [138]. The
former may be explained by the ability of some quinolones
to induce direct mast cell histamine release [138]. The con-
centrations most commonly used for SPT are 5 mg/mL for
levofloxacin, 2 mg/mL for ciprofloxacin, and 1.6 mg/mL
for moxifloxacin. For intradermal tests there is a wide
range of reported concentrations to test with ranging from
dilutions 1/1000 to 1/100 [33,128,138], with some investi-
gators being unable to find non-irritating concentrations
[128,138,139]. Radioimmunoassay and BAT have been
used, but are not widely available yet. BAT, if negative for
the culprit quinolone, is a valuable tool in the decision
whether or not to perform provocation tests (DPT) [140].
The provocation test remains the gold standard in diagno-
sis, despite the risks involved.
Patch tests have had inconsistent and conflicting re-
sults in the diagnosis of non-immediate reactions to
quinolones [125].
Management
Avoidance of the group is usually advised, but a careful
allergy workout with skin tests, RIA and/or BAT if avail-
able, and DPT can confirm tolerance in almost 90% of
patients evaluated [128,140]. Desensitization protocols
have also been reported for ciprofloxacin [141,142].
Rifampicin
Introductory remarks
Allergic reactions to rifampicin were recognized soon
after its introduction, including fever, flu-like syndrome,
rash, thrombocytopenia, acute renal failure, urticaria,
and anaphylactic syndrome.
Epidemiology and risk factors
The incidence of adverse reactions to Rifampicin is vari-
able according to different studies. Hepatitis is one of
the common adverse reactions to rifampicin that occurs
within the initial few weeks of treatment. A meta-
analysis showed that 2.6% of patients who took isoniazid
and rifampicin concomitantly and 1.1% of patients who
took rifampicin exclusively developed hepatitis [143].
Asymptomatic mild elevation of transaminases (<5 times
the upper limit of normal) is common during anti-
tuberculosis treatment and rifampicin can be continued
without disruption.
Pathogenesis
Allergic reactions to rifampicin are mediated by different
immune mechanisms [144]. Urticaria and anaphylaxis
are mediated by type 1 (IgE-mediated) responses [145],
and anti-rifampicin IgE in patients’ serum has been dem-
onstrated by CAP and intradermal skin tests done at the
concentration of 0.006 mg/mL [146,147]. Acute renal
failure, thrombocytopenia and hemolytic anemia may be
mediated by type 2 (antibody-dependent cytotoxicity) re-
sponses. Flu-like syndrome or serum sickness has been
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proposed to be due to type 3 (immune complex) re-
sponses. Hypersensitivity reactions may be involved in
the pathogenesis of rifampicin-induced hepatitis but
other mechanisms such as oxidative metabolism, geno-
types of cytochrome p450 2E1, glutathione S-transferase
M1, and N-acetyl transferase may also be involved [148].
Clinical manifestations
Cutaneous reactions are the most common adverse reac-
tions induced by rifampicin and this drug is a frequent
culprit of skin reactions during anti-tuberculosis treat-
ment. Flushing affecting the face and neck are common
and usually transient. Flu-like syndrome usually begins
within 1-2 hours after each administration; the incidence
is much higher when rifampicin is intermittently admin-
istered, and the majority of patients showing flu-like
syndrome will tolerate rifampicin if administered daily
[89,149]. Other cutaneous manifestations include macu-
lopapular rashes, pemphigus, lupus erythematous, SJS/
TEN, urticaria, and anaphylaxis [89].
Tuberculosis is more prevalent in HIV-positive pa-
tients, and HIV infection is a well known risk factor for
drug allergy. Thrombocytopenia is the most common
hematological adverse reaction and is associated with
anti-rifampicin antibodies that bind to platelet mem-
brane GP1b/IX complex [150]. Rifampicin can induce
various renal toxicities, including acute tubular necrosis,
rapid progressive glomerulonephritis, acute interstitial
nephritis, minimal change nephrotic syndrome and light
chain proteinuria [151]. The adverse reactions are usu-
ally dose-dependent, and some of them occur more fre-
quently when the drug is administered intermittently.
Girling divided the adverse reactions to rifampicin into 2
categories. One group is composed of reactions that
occur with daily administration, such as skin rashes,
gastrointestinal effects, hepatitis and thrombocytopenia.
The second group is constituted by reactions that occur
only with intermittent administration such as flu-like
syndrome, hemolytic anemia, acute renal failure and
anaphylaxis [152].
Diagnosis
Intradermal skin tests with a 1:10,000 dilution, which
has been shown to be non-irritative, have been recom-
mended for the diagnosis of immediate urticarial reac-
tions to rifampicin [153].
Management
For patients with rifampicin allergy various desensi-
tization protocols have been published [97,154]. As ri-
fampicin is one of the key drugs for first line anti-TB
treatment and it is essential for treatment of isoniazid
resistant tuberculosis, desensitization or graded chal-
lenge is frequently required in practice. The Japanese
Society for Tuberculosis recommended a desensitization
protocol which starts from 25 mg, a dose that is usually
recommended at graded challenge, and requires 16 days
to reach the maintenance dose [154]. A multicenter
retrospective study proved the efficacy of this graded
challenge procedure [155]. Other authors reported a
rapid desensitization protocol which starts from 0.1 mg
and requires 6-11 hours to achieve the maintenance
dose [97,156]. In case of serious adverse reactions such
as thrombocytopenia, hemolytic anemia or acute renal
failure desensitization or graded challenge treatment are
contraindicated and rifampicin should be discontinued
permanently.
Streptomycin
Introductory remarks
Although already mentioned in the Aminoglycoside sec-
tion, Streptomycin still remains as one of the active
treatment agents for Mycobacterium tuberculosis, non-
tuberculous Mycobacteria, and brucellosis. Therefore, a
separate section on Streptomycin has been considered
pertinent.
Epidemiology and risk factors
About 1-5% of patients may experience hypersensitivity
reactions. Patients may develop anaphylaxis at a trivial
dose of streptomycin. Exposure to streptomycin through
an impaired skin barrier [30], or during oocyte retrieval
procedure for artificial fertilization [31] can induce ana-
phylaxis. Even skin prick test can induce anaphylaxis, so
SPT should be carried out at a low starting concentra-
tion such as from 1 ng/mL [30,31].
Clinical manifestations
Streptomycin can induce skin rash, anaphylaxis, ototox-
icity and nephrotoxicity. Streptomycin is usually adminis-
tered as a daily low dose (15 mg/kg/day) or intermittent
high dose (25 mg/kg 3 times per week) for treatment of
tuberculosis and the incidence of ototoxicity and nephro-
toxicity are no different when using those two protocols
[157]. Ototoxicity is usually dose-dependent with vestibu-
lar damage and vertigo. The majority of the vestibular tox-
icities are transient. However, hearing loss from cochlear
toxicity may occur and damage may persist despite drug
discontinuation [157]. Streptomycin can induce renal
damage, such as acute tubular necrosis, in 0.1-1% of
patients with tuberculosis and it usually recovers after
discontinuation.
Various additional skin reactions to streptomycin have
been reported including maculopapular exanthema, ery-
thema, urticaria, exfoliative dermatitis, SJS and DiHS
[89].
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Pathogenesis
There is no evidence of streptomycin-specific IgE in-
volved in reactions to this antibiotic. In patients with
haemolytic anemia antistreptomycin IgG antibodies have
been demonstrated by means of Coombs test.
Diagnosis
Skin tests are not validated, but positive reactions have
been observed [27,31]. For cell-mediated reactions to
streptomycin, patch tests with a 20% drug concentration
in petrolatum have been suggested [27,32].
Management
In patients with streptomycin allergy avoidance of the
antibiotic is recommended. Cross-reactions between neo-
mycin, netilmycin, and streptomycin are observed in 1 to
5% of the cases. A 3-hour desensitization protocol with
streptomycin beginning with 1 mg administered intraven-
ously has been proposed [27,38,39].
Sulphamethoxazole – trimethoprim (cotrimoxazole)
Introductory remarks
The combination of the two anti-infectious agents, sulfa-
methoxazole (SMX) and trimethoprim (TRP), is called
cotrimoxazole and is marketed worldwide as Bactrim®,
Septra®, Cotrim® etc. The combination has been claimed
to be superior to each single agent alone, as TRP and
SMX together inhibit successive steps in the folate synthe-
sis pathway (see Figure 1) [158,159]. It is used to treat bac-
terial urinary tract infections, otitis media, bronchitis, skin
and wound infections, traveler's diarrhea, shigellosis and
other infections caused by sensitive organisms. It is also
used to prevent or treat Pneumocystis Jiroveci pneumonia,
toxoplasmosis and nocardiosis in immune-suppressed pa-
tients [159,160] and is an established therapeutic option to
prevent relapses in locoregional granulomatosis with poly-
angiitis [161]. Cotrimoxazole should not be used in
children less than 2 months of age due to the risk of ser-
ious side effects (kernicterus). For the same reason, they
are generally contra-indicated in women prior to delivery,
and in breast-feeding mothers. The usual recommended
Cotrimoxazole dosage in adults is 800 mg SMX/160 mg
TRP every 12 hours.
Epidemiology and risk factors
Cotrimoxazole has been associated with many side ef-
fects [162]. The majority are thought to be due to SMX,
and only rarely to TRP (Table 1). The majority of pa-
tients allergic to sulphamethoxazole can tolerate in fact
trimethoprim but there are few cases of trimethoprim al-
lergy. With regard to presumably allergic side effects, it is
estimated that around 2% of treated patients without
HIV/AIDS develop a hypersensitivity reaction (HR) [163].
As some of these HR are rather severe [164], the use of
cotrimoxazole has decreased substantially, and in some
countries therapy with TRP alone has been advocated.
Different risk factors have been described for cotri-
moxazole hypersensitivity :
- HIV infection increases the incidence of allergic side
effects and also the intensity of the DHR, as the incidence
of SJS/TEN to various drugs including cotrimoxazole is
higher in this patient group than in non HIV infected per-
sons [164]. Treatment with cotrimoxazole (3 x weekly
twice 800/160 mg) as prophylactic treatment of
Figure 1 Effect of cotrimoxazole (Sulfamethoxazole and
Trimethoprim) on folate synthesis.
Table 1 Side effects linked to Sulfamethoxazole and
Trimethoprim (Cotrimoxazole)
Sulfamethoxazole
• General side effects
Nausea, vomiting, anorexia, diarrhoea, hypoglycaemia, hypothyroidism,
neurological reactions including aseptic meningitis, ataxia, benign
intracranial hypertension, convulsions, dizziness. drowsiness, fatigue,
headache, insomnia, mental depression, peripheral or optic
neuropathies, psychoses, tinnitus, vertigo, and pancreatitis.
• Hypersensitivity reactions:
Skin: Exanthema, pruritus, photosensitivity reactions, exfoliative
dermatitis, SJS/TEN, erythema nodosum.
Systemic: DiHS (with involvement of various organs), Henoch Schönlein
purpura, interstitial nephritis (DD crystallisation); anaphylaxis/urticaria.
Blood: eosinophilia, agranulocytosis, aplastic anaemia,
thrombocytopenia, leucopenia, hypothrombinemia, acute haemolytic
anemia (glucose-6-phosphate dehydrogenase deficiency)
Trimethoprim
• General side effects
Nausea, vomiting, anorexia, diarrhea, thrombocytopenia, megaloblastic
anemia, hyperkalemia, rise in serum creatinine.
• Hypersensitivity reactions:
Drug-induced liver injury (cholestatic and hepatocellular hepatitis)
IgE-mediated anaphylaxis
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Pneumocystis Jiroveci pneumonia was widely used in pa-
tients with acquired immunodeficiency before effective
highly active antiretroviral therapy (HAART) was estab-
lished [165]. Up to 50% of these patients developed skin
reactions (mainly “rashes”) of variable intensity. In some
patients continuation of therapy was possible (without ag-
gravation); in other patients the therapy had to be
stopped.
- Dose and duration of treatment influence the manifest-
ation of drug allergy [166,167]. It may well be that the
shorter and more restricted use of cotrimoxazole, which is
nowadays mainly used for 1-3-day treatment of acute cyst-
itis, contributes to the reduced incidence of severe forms
of delayed hypersensitivity (DH) to cotrimoxazole.
- Metabolism: the deficiency of glucose-6-phosphatase is
a well known risk factor for haemolytic complications with
sulphonamide therapy. The metabolism of SMX to react-
ive compounds (first SMX-NHOH, then SMX-NO) is
blocked by glutathione (Figure 2) [168]. The high inci-
dence of “rashes” to cotrimoxazole in HIV + patients had
been linked to low glutathione levels in HIV infected pa-
tients, but this hypothesis remained controversial [165].
The relationship between slow acetylator phenotype and
the manifestation of DH to cotrimoxazole is unclear [169].
Clinical manifestations
Sulfonamides like SMX, sulfapyrine and sulfadoxine are
associated with various side effects, such as nausea,
haemopoietic disorders, porphyria, and hypersensitivity
reactions. Only some of these adverse effects are medi-
ated by immunological mechanisms and are therefore
true allergic reactions.
True allergic reactions of the anaphylactic type (IgE-
mediated urticaria and anaphylaxis) are less common
[170], as are IgG antibody-mediated reactions (mainly
haemolytic anaemia) [171]. The most frequent manifesta-
tions of cotrimoxazole hypersensitivity are due to T-cell
mediated reactions of varying severity [168]. The most
common are “rashes” like maculopapular exanthemas, but
sulfonyl-arylamines may potentially induce life threatening
reactions like SJS/TEN and DiHS [164,172]. SJS/TEN ap-
pear mainly in the second or third week of treatment. The
main features are widespread erythematous macules, flat
atypical targets and detachment of the body surface area.
Figure 2 Sulfonamide chemical structure and metabolism. a: Sulfonamide core structure. It is present as sulfonyl-arylamine, where a
sufonamide is attached to a benzene ring with an unsubstituted amine (-NH2) moiety at the N4 position. Many other drugs may also contain a
sulfonamide (example: furosemide). b: SMX is metabolized intra-hepatically to SMX-NHOH, which is further oxidised to SMX-NO; the later binds
covalently to cystein in proteins.
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The extent of bullous skin lesions is important for the
prognosis, as >30% of the most severe cases succumb to
this severe DH (TEN). DRESS or Drug (induced) Hyper-
sensitivity Syndrome (DHS or DiHS) [172] appears typic-
ally after a drug exposure of >2 to 10 weeks. It is clinically
characterized by skin rash, fever, lymph node swelling,
hepatitis or involvement of other organs (carditis, colitis,
pancreatitis, meningitis). Many patients develop facial
swelling; some have signs of a capillary leak syndrome,
probably related to the excessively high cytokine levels ob-
served during the acute disease. Many patients have acti-
vated lymphocytes in the circulation (lymphoblasts) and
over 70% (but not all) have marked eosinophilia. Mortality
is about 5-10%, and mainly due to liver failure. The clinical
course is often complicated. Symptoms may reappear long
after stopping the culprit drug. These are often related to
reactivation of herpes viruses, in particular human herpes
virus 6 (HHV-6), EBV or CMV [173]. Of importance is
also the intolerance of other drugs/chemicals during the
active phase of DRESS/DiHS, leading to so called flare up
reactions [173].
Pathophysiology of sulfonyl-arylamine allergies
SMX (and the structurally related sulfadoxine, sulfapyr-
ine, a component of sulfasalazine [174], and dapsone,
see above) are sulfonyl-arylamines. They are character-
ized by a sulfonamide moiety directly attached to a ben-
zene ring and an unsubstituted amine (-NH2) at the N4
position (Figure 2a) [174]. The mechanism of sulfonyl-
arylamine hypersensitivity reactions involves IgE, occasion-
ally IgG and different types of T-cell mediated reactions
[168,170,171,174]. SMX is a pro-drug: it is metabolized
intrahepatically (Cytochrome P450 2C9) to SMX-NHOH,
which is further oxidised to SMX-NO (Figure 2b) [168].
SMX-NO is highly reactive by binding to cysteins in sol-
uble and cell bound proteins. It thus can elicit an IgE and/
or a T cell mediated response to modified proteins which
can result in different clinical presentations.
More importantly SMX is able to directly bind to im-
mune receptors. It is a typical example of the p-i concept
(pharmacological interaction with immune receptor con-
cept), namely that a drug can directly bind to the HLA
(p-i HLA) and/or TCR (p-i TCR) and thereby indirectly
or directly elicit T-cell stimulation [168,175].
As immune reactions are directed to the structural com-
ponent, patients with an allergy to a sulfonyl-arylamine
may cross-react with other sulfonyl-arylamines, but not to
sulfonamides in general. Laboratory analysis of T cell reac-
tions and clinical data show that non-sulfonyl-arylamine
drugs like glibenclamide (glyburide), furosemide, and cele-
coxib are not stimulatory in patients allergic to sulfonyl-
arylamides [168,174,176]. The absence of cross-reactivity
between sulfonamide antibiotics and non-antibiotics has
been shown in large cohorts [163] and withholding non-
antibiotic sulfonamides in sulfonamide allergic patients is
no longer standard of care.
Diagnosis
Sulfonamide hypersensitivity reactions are mainly aller-
gies to sulfonyl-arylamines. They can be clinically sus-
pected by the constellation of exposure, timing, patterns
of organ manifestations and underlying conditions.
The majority of SMX reactions involve T cells. An al-
lergy workup is normally recommended 1 to 6 months
after the reaction. It may comprise skin tests and in vitro
tests. The sensitivity of these tests is probably low, but the
specificity is good – which makes a positive result valu-
able. IDT may be helpful in both immediate and non-
immediate reactions. Sulfamethoxazole at a concentration
of 80 mg/mL has been shown to be non-irritating in IDT
[33], but the sensitivity of IDT using SMX in different skin
manifestations is not known. In addition, IDT have a small
risk for eliciting systemic allergic reactions (mostly mild
and transient). Patch testing [177] and Lymphocyte Trans-
formation Tests (LTT) [10] are used in Europe in non-
immediate reactions. The latter seems to have a fairly
good sensitivity and specificity in severe reactions like
DiHS but not in SJS/TEN [10,178].
The risk of patch test (10% in dimethyl sulfoxide or
petrolatum) is negligible; however its sensitivity seems to
be lower than late (24 hr) reading of intradermal tests
[177]. In our experience the LTT seems to be more sen-
sitive and allows also testing compounds in vitro which
are not available for in vivo tests. However, the LTT and
its variants are still rather complex procedures, which
require skilled personnel and experience with the drug
in in vitro assays [10].
Management
In case of assumed hypersensitivity, the presumably
causative drug is generally immediately withdrawn.
However, in mild, non-immediate sulfamethoxazole reac-
tions (rashes) without signs of mucosal or extra-cutaneous
symptoms, the cotrimoxazole treatment may be continued
or re-administered following a “desensitization” protocol.
Such “treating through” or “desensitization” is most often
used in HIV + patients [178,179] and is successful in 44.4-
79% [180]. It requires monitoring for systemic involve-
ment (fever, eosinophilia, lymphadenopathy, hepatitis). In
most cases an immune mediated pathomechanism has
not been shown.
In localized mild exanthems stopping the treatment and
topical corticosteroids plus an antihistamine for 3-6 days
might be sufficient. Patients with sulfonyl-arylamine in-
duced SJS/TEN should be handled like other SJS/TEN
patients and be best referred to specialized (e.g. burn-)
centres experienced in the care of such patients. In severe
non-immediate reactions like DRESS/DiHS the T-cell
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immune system is massively activated and may temporar-
ily react to many “innocuous” drugs with a flare up
[173]. Thus it is our practice to minimize any drug ther-
apy in patients as long as activated lymphocytes are de-
tectable in the circulation. For the treatment of DiHS
with severe organ involvements (e.g. ALAT/ASAT
values > 500) corticosteroids are often used but not
proven as efficacious in studies.
Telithromycin
Introductory remarks
Telithromycin, the first antibacterial agent commercial-
ized from the group of ketolides, is a semisynthetic de-
rivative of the 14-membered macrolide erythromycin
[181]. Telithromycin differs structurally from macrolides
in the substitution of a 3-keto function in place of the L-
cladinose moiety. An aromatic N-substituted carbamate
extension differentiates erythromycin from clarithromy-
cin. Telithromycin is approved for upper and lower re-
spiratory tract infections [182].
Epidemiology and risk factors
Although clinical trials and post-marketing studies have
only detected mild adverse events [183], the incidence of
telithromycin hypersensitivity is not known and the risk
factors have not been identified.
Pathogenesis and clinical manifestations
Considering adverse events, concern exists about telithro-
mycin hepatotoxicity [183]. Of three patients who devel-
oped severe hepatotoxicity within a few days of taking
telithromycin for upper airway infection, one recovered
spontaneously, one required liver transplantation and one
died [184,185]. The histologic examination of two cases
showed massive hepatic necrosis.
Hypersensitivity reactions to macrolides are rare, with
urticaria and angioedema being the most common
symptoms (112,115,183). Descriptions of telithromycin
hypersensitivity are anecdotal [186,187]. A report exists
of a life-threatening immediate-type hypersensitivity re-
action after the first administration of telithromycin pre-
scribed for an upper respiratory tract infection [186].
Shortly after ingestion of this first dose severe shortness
of breath and airway obstruction developed, requiring
adrenalin and intubation. This patient had previously
tolerated erythromycin and azithromycin. The diagnosis
was based on the convincing clinical history and skin
testing or drug provocation tests were not done.
Regarding non immediate hypersensitivity reactions,
TEN has been reported in a 26-year-old woman who re-
ceived telithromycin for sinusitis [188]. She had epider-
mal detachment affecting more than 50% of her total
body surface area and received treatment with intraven-
ous immunoglobulins.
Diagnosis
The diagnosis of telithromycin allergy is based mainly
on drug provocation testing, as skin testing is of little
use [112,115,189].
Management
Although hypersensitivity reactions to telithromycin
are rare they have been reported, including severe hep-
atotoxicity. These observations need to be considered
when prescribing telithromycin.
Tetracyclines
Introductory remarks
Tetracyclines are antimicrobial agents that have been in
use since 1948. They inhibit protein synthesis by interact-
ing with the bacterial ribosome and therefore these antibi-
otics are considered bacteriostatic. The chemical structure
consists of four tetra- hydrocarbon rings with a “cycl”
derivation. They belong to a subclass of polyketide com-
pounds that have an octahydrotetracene-2-carboxamide
skeleton. They are collectively known as derivatives of
polycyclic naphthacene carboxamide [189]. Classical nat-
ural occurring members of this group are: tetracycline,
chlortetracycline, oxytetracycline, declocycline and other
semisynthetic like doxycycline and minocycline [187]. They
are amphoteric antibiotics forming acid or basic salts which
are soluble in water. As they are ampholytes, the optimal
solubility is observed in basic and alkaline solutions [190].
They are used for treating infectious diseases caused
by Gram-negative and Gram-positive bacteria such as
pelvic infections, bronchitis, urinary tract infections, as
well as infections caused by rickettsia, chlamydia and
mycoplasma species. Other indications are acne vulgaris,
bullous pemphigus, rosacea and rheumatoid arthritis
[189]. They cross the placental barrier and can accumu-
late in the long tubular bones and the teeth. These anti-
biotics are contraindicated in children and in women
after the fifth week of pregnancy [191].
Epidemiology, risk factors and clinical manifestations
Amongst the adverse side effects, allergic and auto-
immune drug reactions have been reported [192,193]. In
spite of the adverse effects tetracycline has been shown
to diminish the rash severity in patients treated with epi-
dermal growth factor receptor (EGFR) inhibitors [194].
They have also been implicated in inhibiting the IgE-
mediated responses and in the attenuation of the allergic
response by inhibiting the NF-kB pathway [195].
Pathogenesis
Although classical hypersensitivity reactions are consid-
ered much less common than for beta-lactams and other
antibiotics, tetracyclines have been implicated in both IgE-
[195] and T cell-dependent reactions such as fixed drug
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eruption [196-199], more severe reactions like DiHS and
TEN [200], and reactions involving specific organs such as
liver, lungs, and the central nervous system amongst
others [200]. Some of these severe reactions have been
followed by multiple autoimmune sequelae [199].
Immediate reactions can be anaphylactic when a sus-
pected IgE-mediated mechanism [201] or a non- allergic
hypersensitivity reaction are considered [199,201]. All
these reactions occur within a short interval after drug
intake and tetracycline [202], doxycycline [203], and
minocycline [204] have been implicated. In the case of
minocycline an intermediate metabolite has been postu-
lated as the cause of the reaction although further evalu-
ation is required [192].
All tetracyclines share a polycyclic nucleus although with
different side chains. They may generate common epitopes
responsible for the cross-reactivity or unique structures
that elicit specific selective responses to only a single drug
within the tetracycline group as occurs with beta-lactam
antibiotics [205]. Most of the information concerning cross
reactivity has been reported with fixed drug eruptions, the
most common hypersensitivity reaction induced by these
drugs. Cross reactivity between tetracycline hydrochloride
and oxytetracycline has been reported as well as between
demethylchlortetracycline, doxicycline and minocycline
[192-195,197,202]. This pattern of cross reactivity and se-
lective responses may also occur for the other reactions
such as DiHS or organ specific reactions. No information
is available for immediate reactions.
Typical characteristic adverse effects are phototoxic
and photoallergic reactions. These are T cell responses
directed to photoadducts which originate in the skin.
They usually occur after 5 days of drug administration
although they may appear within hours and develop pro-
gressively spreading over the skin not exposed to ultra-
violet radiation. The most common tetracycline involved
in these reactions has been minocycline. Death can
occur specially in those patients who develop fulminant
hepatitis or respiratory failure [198].
Diagnosis
General principles recommended for in vivo diagnostic
tests can be followed for the diagnosis of hypersensitivity
reactions to tetracyclines [6]. These consist on SPT/IDT
for immediate reactions and IDT/patch testing for non
immediate reactions. For doxycycline, concentrations of
20 mg/mL can be used for SPT and for IDT the maximum
non-irritative concentration recommended is one tenth
dilution of this (2 mg/mL) [6]. Concentrations above these
can induce false positive reactions. Concentrations for
patch testing of 5% w/v or w/w in petrolatum have been
recommended. In the photopatch test the drug is applied
on the back using an aluminum chamber and 48 hours
later irradiation with a UVA lamp is made with a dose of
10 jls/cm2. General recommendations are available for
this procedure [206]. Photopatch tests with doxycycline in
appropriate dilution are useful to confirm photoallergic re-
actions to this antibiotic [207].
Management
In cases of immediate hypersensitivity reactions to tetra-
cyclines these drugs must be withdrawn from the treat-
ment and substituted with alternative drugs with similar
antibacterial spectrum. In view of the lack of sufficient
information on whether selective responses or cross-
reactivity occurs, this is the most conservative and safest
approach that can be recommended.
Vancomycin
Introductory remarks
Vancomycin, a glycopeptide, has been often used in in-
fections with beta-lactam resistant Gram-positive organ-
isms or in beta-lactam allergic patients. Its use continues
to rise with the spread of community and hospital-
acquired methicillin-resistant Staphylococcus aureus as
well as in persistent and moderate-to-severe cases of
Clostridium difficile colitis.
Epidemiology and risk factors
The most common hypersensitivity reaction associated
with vancomycin is the red man syndrome (RMS). The in-
cidence varies between 3.7 and 47% in infected patients
and between 30 and 90% in healthy volunteers who re-
ceived this antibiotic [208,209]. Most severe reactions
occur in patients younger than the age of 40, particularly
in children. Mastocytosis, as well as the use of agents that
activate mast cells, such as opioids, muscle relaxants, and
radiocontrast media, can increase the risk of developing
RMS upon the infusion of vancomycin [210,211].
Immune-mediated immediate and non-immediate reac-
tions to vancomycin seem to be infrequent. IgE-mediated
anaphylaxis due to vancomycin is believed to be rare, al-
though reactions with demonstrable drug-specific IgE
have been described [212-214]. Other reactions, including
hematologic and renal disorders, drug fever, and phlebitis,
can also occur but are uncommon [215,216].
Clinical manifestations
Vancomycin can elicit a large variety of hypersensitivity re-
actions, ranging from localized skin reactions to general-
ized cardiovascular collapse. However, the most frequent
immediate hypersensitivity is the RMS, characterized by
flushing, warmth, pruritus, and hypotension. RMS is a
rate-dependent infusion reaction. Pain, muscle spasms in
the back and chest and dyspnea may also occur. RMS is
rarely life-threatening, but severe cardiovascular toxicity
has been reported. Angioedema, wheezing and respiratory
distress are more common in anaphylaxis than in severe
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RMS, whereas RMS more typically presents with chest
pain causing a sensation of chest tightness [217-220].
Vancomycin can elicit a variety of non-immediate
cutaneous and systemic reactions. SJS, exfoliative derma-
titis, TEN, extensive drug fixed eruption, and leukocyto-
clastic vasculitis have all been described in association
with vancomycin use in case reports. Other forms of
hypersensitivity include DiHS syndrome/DRESS, AGEP,
linear IgA bullous dermatosis and renal disorders
[215,221-226].
Pathogenesis
Vancomycin is responsible for several different types of
immunological and non-immunological hypersensitivity
reactions (Table 2). The RMS results from direct mast
cell and basophil histamine release, can occur without
prior exposure, and is not commonly accompanied by
an increase in serum tryptase [227].
Diagnosis
A detailed clinical history supports an appropriate diag-
nosis and allows the distinction between immediate
and non-immediate reactions. Different from RMS,
IgE-mediated anaphylaxis usually does not occur on the
first administration of the medication. Patients with ana-
phylactic reactions to vancomycin often have a history of
multiple prior exposures.
In vitro tests are generally not useful in the diagnosis
of vancomycin reactions. Elevated plasma histamine and
tryptase may be found in severe RMS, and therefore are
not useful in differentiating RMS from anaphylaxis based
on these levels [227].
Although the value of skin tests appears to be uncer-
tain and false-positive reactions may occur when the
antibiotic is tested in high concentrations, we consider
that the skin testing with appropriate vancomycin con-
centrations may reflect clinical reactivity and provide
supportive evidence for clinical features. A positive skin
test (intradermal skin test) at concentrations of 0.1 mg/
mL or lower is suggestive of drug allergy in the setting
of an appropriate clinical history [227].
Positive vancomycin patch test at a concentration of
0.005% in water has been described in non-immediate
reactions [228].
Management
The early recognition and discontinuation of the drug are
critical. Severe RMS can mimic IgE-mediated anaphylaxis
and requires immediate diagnosis and management [229].
In contrast to true allergic hypersensitivity reactions,
slowing the infusion rate of vancomycin to 500 mg given
over one hour usually reduces the chance of developing
RMS. There are few studies regarding the effectiveness of
antihistamines as premedication to prevent RMS; therefore,
the empiric use of premedication should be avoided except
for cases in which more rapid infusion of vancomycin
(rates exceeding 1 g over one hour) are necessary. In these
cases, the combined use of H1 and H2 antihistamines is
recommended one hour before the infusion [209,230-232].
Various series have been published on successful vanco-
mycin desensitization regimes, both rapid (over hours)
and slow (over days); in particular in patients with opioids
treatment a very successful desensitization protocol has
been used permitting pain control while treating beta-
lactam resistant severe infections [233]. Effective desen-
sitization regimes have been described in the treatment of
vancomycin anaphylaxis. Desensitization to vancomycin
has been successfully performed for both suspected IgE-
mediated reactions and for severe immediate RMS refrac-
tory to pre-medication [208,213,234].
Teicoplanin, another glycopeptide with the same
spectrum of antimicrobial activity, has fewer side effects
compared to vancomycin. Although there have been re-
ports of cross-reactivity in individuals with vancomycin
Table 2 Mechanisms and manifestations of Vancomycin hypersensitivity
Mechanisms Type of reaction based on the time
of onset
Main manifestations due to
vancomycin
Non-immunological
mechanism
Mast cell and basophil histamine
release
Immediate reaction Red man syndrome
Immunological
mechanisms
Type I Immediate reaction Anaphylaxis
Type II Non-immediate reactions Nephritis
Type III Non-immediate reactions Vasculitis*
Type IVa Non-immediate reactions Exfoliative dermatitis
Type IVb Non-immediate reactions Maculo-papular exanthema,
DRESS/DiHS
Type IVc Non-immediate reactions SJS/TEN, hepatitis
Type IVd Non-immediate reactions AGEP
*Unproven.
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and teicoplanin allergy, there have also been reports of
patients with teicoplanin allergy who tolerated vanco-
mycin. RMS is very unusual with teicoplanin and imme-
diate reactions and non-immediate reactions are
infrequent [235].
Concluding remarks
Adverse reactions to non beta-lactam antimicrobials are
relatively frequent. Physicians should be informed on
the potential risks of these medications, and the man-
agement of untoward manifestations when they occur.
Table 3 Adverse reactions to non beta-lactam antimicrobials: clinical picture and diagnostic tests*
Drugs Clinical manifestations Diagnostic
tests
Drug concentrations
Aminoglycosides CD, U, MPE, FDE, TEN, DIHS, ANA PT 1-20%
STs 0.1 ng/mL-20 mg/mL
Chloramphenicol ANA, fever, U, AE, MPE, AGEP, CD, bullous eruption,
EM, FDE, SJS, TEN, bronchospasm, aplastic anemia
STs -
PT 1%
Clindamycin MPE, ANA, U, AE, FDE, bullous eruptions, AGEP,
Sweet’s syndrome, SJS, DIHS
OPT -
PT 10%
Dapsone Methemoglobinemia, agranulocytosis Methemoglobin
measurement
-
Ethambutol Skin rash, ED, U, AE, EM, SJS, TEN, blood
eosinophilia, pulmonary infiltrates, hepatitis,
vomiting, thrombocytopenia, flu-like syndrome,
arthralgia, neuropsychiatric symptoms, optic neuritis
PT 10-50%
Isoniazid MPE, lichenoid rash, flushing, DIHS, SJS, pruritus,
drug fever, peripheral neuropathy, hepatitis
Graded
challenge
-
Macrolides U, AE, RC, ANA, MPE, CD, FDE, TEN STs Erythromycin 0.05 mg/mL
Azithromycin 0.01 mg/mL
Roxythromycin 50 mg/mL
Clarithromycin 0.5 mg/mL
PT 10%
OPT -
Pyrazinamide Flushing, itchy rash, ANA, hepatitis STs 500 mg/mL
Quinolones U, ANA, MPE, FDE, photoallergy, AGEP, SJS, TEN STs Levofloxacin 5 mg/mL
Ciprofloxacin 2 mg/mL
Moxifloxacin 1.6 mg/mL
OPT
Rifampicin Flushing, flu-like syndrome, MPE, pemphigus, lupus erythematosus,
SJS, TEN, ANA, thrombocytopenia, nephrotoxicity, hepatitis,
hemolytic anemia
STs 1: 10000
Streptomycin Skin rash, ANA, ototoxicity, nephrotoxicity, MPE, U, ED, SJS, DIHS PT 20%
Sulphamethoxazole Nausea, haemopoietic disorders, porphyria, ANA, haemolyitc anemia,
MPE, SJS, TEN, DIHS
STs 80 mg/mL
PT 10%
LTT
Telithromycin Hepatotoxicity, U, AE, ANA, TEN OPT -
Tetracyclines FDE, DIHS, TEN, hepatitis, pneumonitis, ANA, phototoxic and
photallergic reactions
STs Doxycicline :prick 20 mg/mL; id: 2
mg/mL
PT 5%
Vancomycin RMS, ANA, SJS, ED, TEN, FDE, vasculitis, DIHS, AGEP, linear IgA
bullous dermatosis, nephropathy
STs 0.1 mg/mL
PT 0.005%
*Concentrations given are drawn from the literature. Many of those have not been validated.
Legend: ANA: anaphylaxis; AE: angioedema; CD: contact dermatitis; DIHS: drug-induced hypersensitivity syndrome (DRESS); EM: erythema multiforme;
ED: exfoliative dermatitis; FDE: fixed drug eruption; LTT: lymphocyte transformation test; MPE: maculopapular exanthema; OPT: oral provocation test;
PT: patch tests; RMS: red man syndrome; RC: rhinoconjunctivitis; SJS: Stevens-Johnson syndrome; STs: skin tests; TEN: toxic epidermal necrolysis; U: urticaria.
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In Table 3 a summary of most common reactions and
suggested diagnostic tests are presented.
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